



The effect of SGLT-2 inhibitors on NAFLD in patients with type 2 diabete



全部

新闻

图片

购物

地图

更多

设置

工具

找到约 85,300 条结果 (用时 0.69 秒)

## Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes ...

[care.diabetesjournals.org/content/early/2018/06/04/dc18-0165.full-text.pdf](https://care.diabetesjournals.org/content/early/2018/06/04/dc18-0165.full-text.pdf) - 翻译此页

2018年6月12日 - Data regarding the effect of SGLT-2 inhibitors on human ... Fifty patients with type 2 diabetes and NAFLD were randomly assigned to .... by the institutional ethics review board ..... incident chronic kidney disease: a systematic.

## Effects of Dapagliflozin on Body Composition and Liver Tests in ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5587885/> - 翻译此页

作者: H Tobita - 2017 - 被引用次数: 7 - 相关文章

2017年7月8日 - Risk factors for NASH include type 2 diabetes mellitus (T2DM) and ... Nonalcoholic steatohepatitis (NASH) is an active form of non-alcoholic fatty liver disease (NAFLD). ... To date, no studies have evaluated the effects of SGLT2 inhibitors ... Eligible patients were administered dapagliflozin for 24 weeks, and ...

## Dapagliflozin and Empagliflozin Ameliorate Hepatic Dysfunction ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5801241/> - 翻译此页

作者: PCH Lee - 2018 - 相关文章

2018年1月10日 - Keywords: Fatty liver, SGLT2 inhibitors, Type 2 diabetes mellitus. Go to: Introduction. Both non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus ..... Although SGLT2i exert a glucose-lowering effect together with weight loss, ..... in people with type 2 diabetes mellitus: a systematic review and

Name of Journal: *World Journal of Diabetes*

Manuscript NO: 42699

Manuscript Type: SYSTEMATIC REVIEW

**SGLT-2 inhibitors in NAFLD patients with type 2 diabetes mellitus: A systematic review**

Henith Raj, Harsh Durgia, Rajan Palui, Sadishkumar Kamalanathan, Sandhiya Selvarajan, Sitanshu Sekhar Kar, Jayaprakash Sahoo

## Abstract

### BACKGROUND

Non-alcoholic fatty liver disease (NAFLD) is a common accompaniment of type 2 diabetes. The existing therapeutic options for NAFLD are not adequate. Hypocaloric diet and exercise is the cornerstone of therapy in NAFLD. Pioglitazone is the only drug recommended in diabetes patients with biopsy proven non-alcoholic steatohepatitis (NASH). The frequent coexistence of NAFLD and type 2 diabetes with their combined adverse health consequences and inadequate therapeutic

## Match Overview

1	Crossref 75 words Monique Mendelson, Sébastien Bailly, Mathieu Marillier, Patricia Flore et al. "Obstructive Sleep Apnea Syndrome, O	2%
2	Crossref 37 words Parker, Jack, Val Harpin, Gill Wales, and Nevyne Chalhou b. "The long-term outcomes of interventions for the mana	1%
3	Crossref 27 words R. Palui, J. Sahoo, S. Kamalanathan, S. S. Kar, S. Selvarajan, H. Durgia. "Effect of cabergoline monotherapy in C...	1%
4	Internet 25 words crawled on 13-Oct-2015 <a href="http://www.cshp.ca">www.cshp.ca</a>	1%
5	Internet 22 words crawled on 29-Aug-2016 <a href="http://rheumatology.oxfordjournals.org">rheumatology.oxfordjournals.org</a>	1%
6	Internet 21 words crawled on 04-Nov-2017 <a href="http://onlinelibrary.wiley.com">onlinelibrary.wiley.com</a>	1%
7	Crossref 20 words Loomba, Rohit, Claude B. Sirlin, Brandon Ang, Ricki Bettencourt, Rashmi Jain, Joanie Salotti, Linda Soaft, Jonath	1%
8	Crossref 20 words Matteo Monami, Francesco Liistro, Alessia Scatena, Besmir Nreu, Edoardo Mannucci. "Short and medium-term eff	1%
9	Crossref 12 words Scheen, A.J., and N. Paquot. "Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: A review of the	<1%



[全部](#)[新闻](#)[图片](#)[购物](#)[地图](#)[更多](#)[设置](#)[工具](#)

找到约 91,100 条结果 (用时 0.74 秒)

### Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes ...

[care.diabetesjournals.org/content/early/2018/06/04/dc18-0165.full-text.pdf](https://care.diabetesjournals.org/content/early/2018/06/04/dc18-0165.full-text.pdf) - 翻译此页

2018 - 被引用次数 : 18 - 相关文章

2018年6月12日 - Sodium-glucose cotransporter 2 (SGLT-2) inhibitors have been shown to ... the empagliflozin group (standard treatment for type 2 diabetes plus ... Nonalcoholic fatty liver disease (NAFLD) often coexists with type 2 ... by the institutional ethics review board ... incident chronic kidney disease: a systematic.

### Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6063173/> - 翻译此页

作者 : M Dharmalingam - 2018 - 被引用次数 : 1

Nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes (T2DM) often ... Patients with NASH (but not NAFL) have an increased liver-related mortality ... liver vs. nonalcoholic steatohepatitis: A systematic review and meta-analysis ... lpragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and ...

Abstract · DEFINITION OF ... · RISK FACTORS FOR ... · NONALCOHOLIC FATTY ...

### Non-alcoholic Fatty Liver Disease: A Review of Anti-diabetic ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6018310/> - 翻译此页

作者 : HS Snyder - 2018 - 被引用次数 : 2 - 相关文章

2018年3月25日 - Patients with concurrent NAFLD and type 2 diabetes mellitus have a ... lpragliflozin is an SGLT2 inhibitor currently available in Japan, but not in the United States. ... Nonalcoholic fatty liver disease: a systematic review. JAMA ...

### <sup>[PDF]</sup> Antidiabetic Drugs in NAFLD: The Accomplishment of Two Goals at ...

<https://www.mdpi.com/1424-8247/11/4/121/pdf> ▼ 翻译此页

作者 : M Tacelli - 2018

2018年11月8日 - of 55% in patients with type 2 diabetes mellitus (T2DM). ... DPP-4 and SGLT inhibitors were published. No ... steatosis to non-alcoholic steatohepatitis (NASH) and liver cirrhosis

找到约 67,300 条结果 (用时 0.66 秒)

### **[PDF] Antidiabetic Drugs in NAFLD: The Accomplishment of Two Goals at ...**

<https://www.mdpi.com/1424-8247/11/4/121/pdf> - 翻译此页

作者 : M Tacelli - 2018

2018年11月8日 - of 55% in **patients with type 2 diabetes mellitus** (T2DM). ... DPP-4 and **SGLT inhibitors** were published. No ... steatosis to non-alcoholic steatohepatitis (NASH) and liver cirrhosis, is the most common ..... metabolism and cardiovascular risk in **non-alcoholic fatty liver disease** (NAFLD): A **systematic review** and.

### **Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus**

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6063173/> - 翻译此页

作者 : M Dharmalingam - 2018 - 被引用次数 : 1

**Nonalcoholic fatty liver disease** (NAFLD) and **type 2 diabetes** (T2DM) often ... **Patients** with NASH (but not NAFL) have an increased liver-related mortality ..... liver vs. nonalcoholic steatohepatitis: A **systematic review and** meta-analysis ..... Ipragliflozin, an **SGLT2 inhibitor**, exhibits a prophylactic effect on hepatic steatosis and ...

Abstract · DEFINITION OF ... · RISK FACTORS FOR ... · NONALCOHOLIC FATTY ...

### **Non-alcoholic Fatty Liver Disease: A Review of Anti-diabetic ...**

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6018310/> - 翻译此页

作者 : HS Snyder - 2018 - 被引用次数 : 2 - 相关文章

2018年3月25日 - **Patients** with concurrent NAFLD and **type 2 diabetes mellitus** have a ..... Ipragliflozin is an **SGLT2 inhibitor** currently available in Japan, but not in the United States. .... **Nonalcoholic fatty liver disease: a systematic review**. JAMA ...

### **Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes ...**

[care.diabetesjournals.org/content/41/8/1801](https://care.diabetesjournals.org/content/41/8/1801) - 翻译此页

作者 : MS Kuchay - 2018 - 被引用次数 : 18 - 相关文章

**Nonalcoholic fatty liver disease** (NAFLD) often coexists with **type 2 diabetes** (1). ... The data on **SGLT-2 inhibitors** and human liver fat are scarce; therefore, this ..... risk of incident chronic kidney disease: a **systematic review and** meta-analysis.

### **Non-alcoholic fatty liver disease and diabetes - ScienceDirect**

<https://www.sciencedirect.com/science/article/pii/S0026049516000044> - 翻译此页

作者 : JM Hazlehurst - 2016 - 被引用次数 : 94 - 相关文章

**Non-alcoholic fatty liver disease** (NAFLD) and **type 2 diabetes** (T2DM) are common ... Therapeutic disease modifying options for **patients** with NAFLD are currently limited. ... In this **review**, we have